Piramal Pharma share price
NSE: PPLPHARMABSE: 543635Pharmaceuticals & BiotechnologySmall Cap
Share price at the NSE close on 23 Oct 2026. Previous close ₹194.99.
- Next results date: the board meets on 27 Oct 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹25,438 Cr331st largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 28 Apr 2026
- 3.1
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 29 Jul 2026
- −3.9%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹217 crore of one-off items, the largest of them in the quarter to Mar 2026.
- −1.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 29 Jul 2026
- 1.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 28 Apr 2026
- 0.67
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 24,65,51342.5% delivered
Results
Consolidated; ₹ crore, the charts by years to March, the table by quarter.Quarterly results
Quarter to Jun 2026, against the quarter beforeFiled 29 Jul
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹2,270 Crdown 17.51%
- Net profitNet profit. Under it, net profit in the quarter before. A change in per cent is not worked out where either period is a loss or nothing.
- −₹69 CrQuarter to Mar 2026: −₹8.82 Cr
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- −3.1%
Revenue by year
Net profit by year, a loss in red
- Net profit
- Loss
| ₹ crore | Sep 2024Filed 24 Oct | Dec 2024Filed 28 Jan | Mar 2025Filed 12 Jun | Jun 2025Filed 28 Jul | Sep 2025Filed 5 Nov | Dec 2025Filed 29 Jan | Mar 2026Filed 28 Apr | Jun 2026Filed 29 Jul |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2,242 | 2,204 | 2,754 | 1,934 | 2,044 | 2,140 | 2,752 | 2,270 |
| Net profit | 23 | 4 | 154 | −82 | −99 | −136 | −9 | −69 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 1.0% | 0.2% | 5.6% | −4.2% | −4.9% | −6.4% | −0.3% | −3.1% |
Business segments
In the year to Mar 2026 the company reports one business segment, Pharmaceuticals, which carries all its revenue.
Valuation
Today, against the company's own history. Not shown, P/E: loss, last twelve months.PE ratio and valuation history
At or below today's level on 60% of 900 trading days since Nov 2022.
At or below today's level on 85% of 727 trading days over the last 3 years.
At or below today's level on 49% of 967 trading days since Nov 2022.
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −39.2% | – | – | 0.0% |
| 3 years | +25.9% | – | – | 0.0% |
Mutual funds holding it
103 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 55 of the 64 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future. 2 more funds filed their first portfolio on record, holding it.Mutual fund holdings
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 2
- Bought againBought again. Funds that held it at the month's end, had not held it the month before, and held it in an earlier month.
- 3
- AddedAdded. Funds that held more shares than at the end of the month before.
- 23
- CutCut. Funds that held fewer shares than at the end of the month before.
- 41
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 32
- Sold outSold out. Funds that held it at the end of the month before and hold none at this month's end.
- 6
| Fund | |||
|---|---|---|---|
 HDFC Flexi Cap FundHDFC Mutual Fund | 7,18,36,476 | 1.37% | ₹1,483.6 Cr |
 Nippon India Pharma FundNippon India Mutual Fund | 99,37,272 | 2.24% | ₹205.2 Cr |
 Bandhan Small Cap FundBandhan Mutual Fund | 98,96,924 | 0.57% | ₹204.4 Cr |
 Franklin India Opportunities FundFranklin Templeton Mutual Fund | 61,54,389 | 1.33% | ₹127.1 Cr |
 Bajaj Finserv Flexi Cap FundBajaj Finserv Mutual Fund | 60,21,499 | 1.46% | ₹124.4 Cr |
 Canara Robeco Small Cap FundCanara Robeco Mutual Fund | 56,30,453 | 0.83% | ₹116.3 Cr |
| Franklin India Small Cap FundFranklin Templeton Mutual Fund | 51,09,343 | 0.74% | ₹105.5 Cr |
| Nippon India Small Cap FundNippon India Mutual Fund | 49,90,259 | 0.13% | ₹103.1 Cr |
 ICICI Prudential Multi Cap FundICICI Prudential Mutual Fund | 45,65,035 | 0.50% | ₹94.3 Cr |
| Canara Robeco Aggressive Hybrid FundCanara Robeco Mutual Fund | 31,50,000 | 0.60% | ₹65.1 Cr |
Peers and competitors
Pharmaceuticals, 216 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Piramal Pharma in market cap.
Piramal Pharma is not on the chart: it has no P/E today
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 Emcure PharmaceuticalsEMCURE | 33,586 | 33.2 | 6.8 | 17.5 | +18.4% | +35.9% | 21.5% | 25.2% | 0.20% |
 Sai Life SciencesSAILIFE | 29,639 | 81.9 | 11.9 | 45.0 | – | – | 15.7% | 18.7% | 0.00% |
 WockhardtWOCKPHARMA | 29,276 | 71.6 | 5.9 | 40.4 | +18.4% | – | 8.8% | 7.4% | 0.00% |
 Acutaas ChemicalsACUTAAS | 25,689 | 66.5 | 15.5 | 47.0 | +40.9% | +104.3% | 26.1% | 29.1% | 0.08% |
 Neuland LaboratoriesNEULANDLAB | 24,204 | 48.6 | 12.9 | 31.5 | +78.3% | +182.6% | 29.3% | 32.1% | 0.18% |
 Rubicon ResearchRUBICON | 23,578 | 81.8 | 18.3 | 52.2 | – | – | 22.4% | 25.8% | 0.11% |
 Granules IndiaGRANULES | 21,679 | 32.7 | – | – | +24.8% | +38.1% | 15.1% | 15.1% | 0.22% |
 Cohance LifesciencesCOHANCE | 17,211 | 162.0 | 4.4 | 54.8 | +41.2% | −58.5% | 3.8% | 3.0% | 0.00% |
Dividends
Per share, by the year it was paid for, and the latest payments.Dividend history and dates
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up.| Ex-date | Type | Per share |
|---|---|---|
| 16 Jul 2025 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹0.14 |
| 12 Jul 2024 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹0.11 |
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
16 Oct · Analysts
1 Oct · News Verification
The exchange asked on 30 Sep 2026
Sep 2026
Piramal Pharma share price by year
Each calendar year to 2025.Piramal Pharma share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 172.21 | −35.3% | 258.25 | 166.52 |
| 2024 | 266.25 | +91.8% | 293.55 | 115.50 |
| 2023 | 138.85 | +21.1% | 140.50 | 63.95 |
| 2022 | 114.65 | – | 190.00 | 114.50 |
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on NSE.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 23 Oct 2026 | 194.00 | 194.91 | 185.02 | 191.07 | 189.86 | 24,65,513 | 42.5% |
| 22 Oct 2026 | 190.51 | 196.35 | 188.22 | 194.99 | 193.35 | 28,35,616 | 31.8% |
| 21 Oct 2026 | 194.95 | 199.50 | 189.60 | 191.19 | 193.97 | 31,66,061 | 41.1% |
| 19 Oct 2026 | 197.00 | 201.73 | 193.81 | 194.44 | 197.40 | 13,18,209 | 37.9% |
| 16 Oct 2026 | 194.95 | 198.75 | 193.60 | 197.73 | 197.08 | 20,49,052 | 44.4% |
| 15 Oct 2026 | 193.50 | 196.39 | 192.62 | 194.43 | 194.29 | 29,95,160 | 74.9% |
| 14 Oct 2026 | 195.35 | 196.70 | 192.76 | 193.94 | 194.43 | 16,89,308 | 54.6% |
| 13 Oct 2026 | 196.40 | 197.00 | 191.41 | 196.01 | 194.20 | 13,90,936 | 39.8% |
| 12 Oct 2026 | 197.29 | 199.50 | 194.80 | 196.66 | 196.62 | 14,79,408 | 38.1% |
| 9 Oct 2026 | 197.00 | 199.00 | 194.02 | 196.88 | 196.93 | 13,96,417 | 32.5% |
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Rights issue history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 2 Aug 2023 | Rights issue | – | Shareholders were offered new shares. Noted, not adjusted for. |
About Piramal Pharma
Piramal Pharma Limited is a pharmaceutical, health and wellness company. It sells products and services to drug developers, hospitals and consumers, and has a commercial presence in more than 100 countries. It employs over 7,000 people.
The business is organised in three parts: a contract development and manufacturing organisation (CDMO), complex hospital generics, and consumer healthcare. Piramal Pharma Solutions is the CDMO. It has 15 development and manufacturing facilities in North America, the UK and Europe, and India, and works with more than 500 customers. Piramal Critical Care makes inhalation anesthetics, intrathecal therapy for spasticity management, injectable pain management drugs and other generic and speciality products. Its products are sold in more than 6,000 hospitals, surgical centres and veterinary clinics. Piramal Consumer Healthcare sells over 25 brands in India across categories such as kids' wellness, skincare and geriatric care, and has a manufacturing and distribution partnership with Bayer Pharmaceuticals Private Limited.
It was incorporated in 2020. Under a composite scheme of arrangement sanctioned by the National Company Law Tribunal, Mumbai Bench, on 12 August 2022, shareholders of Piramal Enterprises Limited were allotted four shares of the company for every one share they held. In the year to March 2026, the company acquired Kenalog, an injectable corticosteroid product, from Bristol Myers Squibb.
The company is part of the Piramal Group, which has a presence in financial services, pharmaceuticals and real estate, with operations in over 30 countries.
- Legal name
- Piramal Pharma Limited
- NSE symbol
- PPLPHARMA
- BSE code
- 543635
- ISIN
- INE0DK501011
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- Oct 2022
- Face value
- ₹10
- CIN
- L24297MH2020PLC338592
- Corporate identity number, the registrar of companies' code for it